Marcy-l'etoile, France
Marcy-l'etoile, France

bioMérieux is a multinational biotechnology company founded and headquartered in France. A subsidiary of Institut Mérieux, bioMérieux is listed on the NYSE Euronext Paris stock exchange. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with the AIDS causing Human Immuno-deficiency Virus (HIV). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of HIV-1 nucleic acid. The oligonucleotide sequences provided with the present invention are located in the LTR part of the HIV viral genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of HIV-1 can be obtained. The benefit of the sequences of the present invention primarily resides in the fact that, with the aid of primers and probes comprising the sequences according to the invention the nucleic acid of all presently known subtypes of HIV-1 can be detected with high accuracy and sensitivity. So far no primer pairs or hybridization probes have been developed that would allow the detection of such a broad range of HIV-1 variants. The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.


Patent
bioMerieux | Date: 2015-07-29

A method of preparing a characterization zone of an analysis plate to carry out a characterization of a population of a microorganism in the presence of an antimicrobial agent by mass spectrometry using the MALDI technique. The method involves the following steps in succession: a step for providing an analysis plate for a characterization by means of the MALDI technique, the plate including an analysis zone carrying an antimicrobial agent; a step of depositing the population of a microorganism onto said analysis zone in contact with the antimicrobial agent; an incubation step of preserving the analysis plate under conditions and for a sufficient time to allow the antimicrobial agent and the microorganism that is present to interact; and a step of depositing a matrix that is suitable for the MALDI technique onto the analysis zone; associated characterization and functionalization methods, analysis plates and uses.


Patent
bioMerieux, Aix - Marseille University and French National Center for Scientific Research | Date: 2015-08-03

The invention provides a novel method of preparing a capture phase for detecting and/or quantifying a target biological entity, said capture phase including a biological ligand for the biological entity, said biological ligand being covalently bonded to an amphiphilic polymer and being immobilized on a solid support, the method being characterized in that the biological ligand is immobilized on the solid support by bringing the solid support into contact with a dispersion of micelles formed by a plurality of chains of the amphiphilic polymer, said micelles carrying a plurality of molecules of the biological ligand on the surface thereof. The invention also provides corresponding capture phases and associated detection methods and kits.


Patent
bioMerieux | Date: 2016-02-09

Chimera proteins including: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.


A method for distinguishing among a first group of microorganisms belonging to a first taxon of Gram negative bacteria, the first group of bacteria exhibiting a mechanism of resistance to a treatment; a second group of microorganisms belonging to a second taxon of Gram negative bacteria, the second taxon of bacteria being different than said first taxon, and exhibiting a mechanism of resistance to a treatment identical to the mechanism of the first group; and a third group of Gram negative bacteria that is not resistant to the treatment.


The present invention pertains to a method of detection, by mass spectrometry, of at least one marker of at least one mechanism of resistance to at least one antimicrobial, resistance of at least one microorganism contained in a sample, characterised in that the antimicrobial is a cephalosporin, and said resistance markers are proteins or peptides. Preferably, said proteins or peptides are proteins from said microorganism.


The present invention pertains to a method of detection, by mass spectrometry, of at least one marker of at least one mechanism of resistance to at least one antimicrobial, resistance of at least one microorganism contained in a sample, characterised in that the antimicrobial is a carbapenem, and said resistance markers are proteins or peptides. Preferably, said proteins or peptides are proteins from said microorganism.


The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with the AIDS causing Human Immuno-deficiency Virus (HIV). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of HIV-1 nucleic acid. The oligonucleotide sequences provided with the present invention are located in the LTR part of the HIV viral genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of HIV-1 can be obtained. The benefit of the sequences of the present invention primarily resides in the fact that, with the aid of primers and probes comprising the sequences according to the invention the nucleic acid of all presently known subtypes of HIV-1 can be detected with high accuracy and sensitivity. So far no primer pairs or hybridization probes have been developed that would allow the detection of such a broad range of HIV-1 variants. The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.


Patent
bioMerieux | Date: 2015-03-23

An antimicrobial compound, as well as the salts, derivatives and analogues thereof, said compound being represented by the general formula (I):


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-24-2015 | Award Amount: 18.47M | Year: 2016

The management of febrile patients is one of the most common and important problems facing healthcare providers. Distinction between bacterial infections and trivial viral infection on clinical grounds is unreliable, and as a result innumerable patients worldwide undergo hospitalization, invasive investigation and are treated with antibiotics for presumed bacterial infection when, in fact, they are suffering from self-resolving viral infection. We aim to improve diagnosis and management of febrile patients, by application of sophisticated phenotypic, transcriptomic (genomic, proteomic) and bioinformatic approaches to well characterised large-scale, multi-national patient cohorts already recruited with EU funding. We will identify, and validate promising new discriminators of bacterial and viral infection including transcriptomic and clinical phenotypic markers. The most accurate markers distinguishing bacterial and viral infection will be evaluated in prospective cohorts of patients reflecting the different health care settings across European countries. By linking sophisticated new genomic and proteomic approaches to careful clinical phenotyping, and building on pilot data from our previous studies we will develop a comprehensive management plan for febrile patients which can be rolled out in healthcare systems across Europe.

Loading bioMerieux collaborators
Loading bioMerieux collaborators